Praluent (alirocumab) — United Healthcare
Homozygous familial hypercholesterolemia (HoFH)
Initial criteria
- Diagnosis of homozygous familial hypercholesterolemia
- Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis)
- Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [e.g., Repatha (evolocumab)]
- Not used in combination with Juxtapid (lomitapide)
Reauthorization criteria
- Documentation of positive clinical response to Praluent therapy
- Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
- Not used in combination with Juxtapid (lomitapide)
Approval duration
12 months